RPg Family Wealth Advisory LLC Purchases New Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

RPg Family Wealth Advisory LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 32,942 shares of the biopharmaceutical company's stock, valued at approximately $1,886,000.

Several other hedge funds have also recently bought and sold shares of the business. Congress Asset Management Co. grew its position in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock valued at $139,298,000 after purchasing an additional 1,988,238 shares during the last quarter. Handelsbanken Fonder AB grew its position in shares of Halozyme Therapeutics by 76.9% in the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company's stock valued at $112,715,000 after purchasing an additional 856,200 shares during the last quarter. Boston Trust Walden Corp acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $23,211,000. Swedbank AB acquired a new stake in shares of Halozyme Therapeutics in the first quarter valued at about $13,927,000. Finally, Dimensional Fund Advisors LP grew its position in shares of Halozyme Therapeutics by 12.4% in the second quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock valued at $99,363,000 after purchasing an additional 209,530 shares during the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

HALO traded up $0.68 during midday trading on Wednesday, reaching $48.47. 963,013 shares of the company's stock were exchanged, compared to its average volume of 1,375,309. The firm has a market capitalization of $6.17 billion, a price-to-earnings ratio of 15.82, a price-to-earnings-growth ratio of 0.43 and a beta of 1.29. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The business has a 50-day simple moving average of $54.00 and a two-hundred day simple moving average of $53.71.

Analysts Set New Price Targets

HALO has been the topic of several research analyst reports. Benchmark reaffirmed a "buy" rating and issued a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. HC Wainwright reiterated a "buy" rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. TD Cowen increased their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and increased their target price for the company from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Wells Fargo & Company cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and increased their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.11.

Insiders Place Their Bets

In other news, CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $59.09, for a total transaction of $590,900.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares of the company's stock, valued at approximately $39,988,802.96. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 60,000 shares of company stock worth $3,425,000 over the last quarter. Company insiders own 2.70% of the company's stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.